Cargando…

Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression

Background and Objectives: There is evidence for ketamine efficacy in treatment-resistant depression (TRD). Several safety and tolerability concerns arise that some psychotropic agents may provide blood pressure or/and heart rate alterations. The aim of this study is to review blood pressure measure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szarmach, Joanna, Cubała, Wiesław Jerzy, Włodarczyk, Adam, Gałuszko-Węgielnik, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002231/ https://www.ncbi.nlm.nih.gov/pubmed/33809766 http://dx.doi.org/10.3390/medicina57030274

Ejemplares similares

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression
por: Szarmach, Joanna, et al.
Publicado: (2020)

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression
por: Włodarczyk, Adam, et al.
Publicado: (2021)

Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study
por: Włodarczyk, Adam, et al.
Publicado: (2021)

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression
por: Wilkowska, Alina, et al.
Publicado: (2021)

Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases
por: Gałuszko-Wȩgielnik, Maria, et al.
Publicado: (2021)

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
por: Wilkowska, Alina, et al.
Publicado: (2021)

Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression
por: Słupski, Jakub, et al.
Publicado: (2020)

Magnesium in Ketamine Administration in Treatment-Resistant Depression
por: Górska, Natalia, et al.
Publicado: (2021)

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
por: Gałuszko-Węgielnik, Maria, et al.
Publicado: (2023)

Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder
por: Gałuszko-Wȩgielnik, Maria, et al.
Publicado: (2023)

Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms
por: Włodarczyk, Adam, et al.
Publicado: (2023)

Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis
por: Włodarczyk, Adam, et al.
Publicado: (2020)

Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review
por: Kwaśny, Aleksander, et al.
Publicado: (2023)

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review
por: Wilkowska, Alina, et al.
Publicado: (2020)

Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor
por: Cubała, Wiesław Jerzy, et al.
Publicado: (2010)

The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine
por: Wilkowska, Alina, et al.
Publicado: (2022)

Multiple Comorbidity Profile of Psychiatric Disorders in Epilepsy
por: Grzegorzewska, Agata M., et al.
Publicado: (2021)

Residual insomnia in major depressive disorder: a systematic review
por: Kwaśny, Aleksander, et al.
Publicado: (2023)

Severe skin complications in patients treated with antidepressants: a literature review
por: Herstowska, Marta, et al.
Publicado: (2014)

No relationship between baseline salivary alpha-amylase and State-Trait Anxiety Inventory Score in drug-naïve patients with short-illness-duration first episode major depressive disorder: An exploratory study
por: Szarmach, Joanna, et al.
Publicado: (2017)

Gut Microbiota in Depression: A Focus on Ketamine
por: Wilkowska, Alina, et al.
Publicado: (2021)

Dietary Patterns of Treatment–Resistant Depression Patients
por: Mechlińska, Agnieszka, et al.
Publicado: (2022)

Dysphoria and Irritability—Diagnostic Pitfalls in the Assessment of Interictal Dysphoric Disorder in Epilepsy
por: Grzegorzewska, Agata M., et al.
Publicado: (2021)

Ketogenic Diet: A Dietary Modification as an Anxiolytic Approach?
por: Włodarczyk, Adam, et al.
Publicado: (2020)

Ketamine in Bipolar Disorder: A Review
por: Wilkowska, Alina, et al.
Publicado: (2020)

Changes in T-Cell Subpopulations and Cytokine Levels in Patients with Treatment-Resistant Depression—A Preliminary Study
por: Szałach, Łukasz Piotr, et al.
Publicado: (2022)

Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review
por: Wilkowska, Alina, et al.
Publicado: (2022)

Comment on ‘The overlapping relationship among depression, anxiety, and somatic symptom disorder and its impact on the quality of life of people with epilepsy’
por: Grzegorzewska, Agata M., et al.
Publicado: (2023)

Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series
por: Al Shirawi, Maryam I., et al.
Publicado: (2017)

Heart rate variability and incidence of depression during the first six months following first myocardial infarction
por: Wilkowska, Alina, et al.
Publicado: (2019)

Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine
por: Zhou, Yanling, et al.
Publicado: (2021)

Diverse clinical presentations of neurosyphilis: focus on differential diagnosis
por: Chrząszcz-Włodarczyk, Agnieszka, et al.
Publicado: (2017)

Somatic Comorbidity of Anxious and Depressed Miners
por: Becarevic, N., et al.
Publicado: (2022)

Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities
por: Veraart, Jolien K E, et al.
Publicado: (2021)

Somatic comorbidity, metabolic syndrome, cardiovascular risk, and CRP in patients with recurrent depressive disorders
por: Topić, Radmila, et al.
Publicado: (2013)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders
por: Wichniak, Adam, et al.
Publicado: (2021)

The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression
por: Hashimoto, Kenji
Publicado: (2014)

The Efficacy and Safety of Procedural Sedoanalgesia with Midazolam and Ketamine in Pediatric Hematology
por: Gelen, Sema Aylan, et al.
Publicado: (2015)

Exploring the Relationship between Mood Disorders and Coexisting Health Conditions: The Focus on Nutraceuticals
por: Mechlińska, Agnieszka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3jn91gfo6c8q883b5ac5e5f9k